INSYN1: A Potential Drug Target and Biomarker for the Treatment of Psychiatric Disorders

Target Name: INSYN1

NCBI ID: G388135

INSYN1

INSYN1: A Potential Drug Target and Biomarker for the Treatment of Psychiatric Disorders

Abstract:

INSYN1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for the treatment of psychiatric disorders. Its function as an inhibitory synaptic factor 1 (ISF1) has been extensively studied, providing insights into the underlying mechanisms of psychiatric disease. This article will summarize the current understanding of INSYN1, its potential drug target properties, and its potential as a biomarker for the diagnosis and treatment of psychiatric disorders.

Introduction:

Psychiatric disorders, including depression, anxiety, and schizophrenia, affect millions of individuals worldwide and have a significant impact on quality of life. Although current treatment options offer some relief, the relapse rates and chronicity of these disorders remain a significant public health issue. Therefore, the search for new, effective treatments and biomarkers is critical.

INSYN1: A Potential Drug Target and Biomarker

INSYN1, also known as transcript variant 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of psychiatric disorders. Its function as an ISF1 has been extensively studied, providing insights into the underlying mechanisms of psychiatric disease.

The ISF1 gene, which encodes INSYN1, has been shown to play a crucial role in the development and progression of psychiatric disorders. ISF1 is a key regulator of synaptic plasticity, which is the ability of the brain to change and adapt over time. In addition to its role in synaptic plasticity, ISF1 has also been shown to play a role in the regulation of inflammation and neuroprotection.

Potential Drug Target:

The potential drug target for INSYN1 is its function as an ISF1, which has been shown to contribute to the development and progression of psychiatric disorders. ISF1 has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity, which is critical for the development of psychiatric disorders. Therefore, inhibiting INSYN1 activity may offer a potential therapeutic approach for the treatment of psychiatric disorders.

Biomarker:

INSYN1 has also been identified as a potential biomarker for the diagnosis and treatment of psychiatric disorders. The levels of INSYN1 have been shown to be altered in individuals with psychiatric disorders, providing a potential target for diagnostic tests and the assessment of disease severity. Additionally,INSYN1 has been shown to be a potential biomarker for the treatment of psychiatric disorders, with studies showing that inhibiting INSYN1 activity may offer a potential therapeutic approach for the treatment of psychiatric disorders.

Conclusion:

INSYN1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of psychiatric disorders. Its function as an ISF1 has been extensively studied, providing insights into the underlying mechanisms of psychiatric disease. The potential drug target properties of INSYN1 and its potential as a biomarker for the diagnosis and treatment of psychiatric disorders make it an attractive target for further research.

Targeting INSYN1 may offer a new and effective approach for the treatment of psychiatric disorders, with potential implications for the development of new treatments and therapies. Further research is needed to fully understand the role of INSYN1 in the development and progression of psychiatric disorders, as well as its potential as a biomarker for the diagnosis and treatment of these disorders.

Protein Name: Inhibitory Synaptic Factor 1

Functions: Component of the protein machinery at the inhibitory synapses, probably acting as a scaffold. Inhibitory synapses dampen neuronal activity through postsynaptic hyperpolarization. This synaptic inhibition is fundamental for the functioning of the central nervous system, shaping and orchestrating the flow of information through neuronal networks to generate a precise neural code

The "INSYN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INSYN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets